Form 4: Amgen CEO Robert Bradway Reports Stock Disposals to Cover Tax Obligations

Amgen's CEO, Robert Bradway, reported disposing of shares to cover tax obligations related to vested restricted stock units and dividend equivalents.

Summary

• Robert Bradway, the Chairman, CEO, and President of Amgen Inc., filed a Form 4 detailing changes in his beneficial ownership of Amgen stock.
• On May 2, 2025, Bradway disposed of 2,481 shares of common stock at a price of $283.78 to cover tax obligations.
• An additional 2,352 shares were disposed of on the same date at the same price for the same reason.
• Following these transactions, Bradway directly owns 400,188 shares of Amgen common stock.
• He also indirectly owns 90,000 shares through a GRAT (Grantor Retained Annuity Trust) and another 90,000 shares through a spousal GRAT.
• The reported shares include 1,424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.

Stakeholder Impact

• The stock disposal may have a minor impact on shareholders due to the increased supply of shares, but it is unlikely to be significant given the relatively small number of shares involved.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Disposal, Robert Bradway, Amgen, AMGN, CEO, Tax Obligations, Dividend Equivalents, GRAT